Author: Jessica.F

On May 15, 2020, Hardouin, Christophe; Baillard, Sandrine; Bariere, Francois; Craquelin, Anthony; Grandjean, Mathieu; Janvier, Solenn; Le Roux, Stephane; Penloup, Christine; Russo, Olivier published an article.Quality Control of 3-Nitro-4-chlorobenzenesulfonamide The title of the article was Multikilogram Synthesis of a Potent Dual Bcl-2/Bcl-xL Antagonist. 2. Manufacture of the 1,3-Diamine Moiety and Improvement of the Final Coupling Reaction. And the article contained the following:

This paper describes the synthesis of kilogram quantities of the sulfonamide moiety I involved in a coupling reaction with acid moiety II to provide batches of drug candidate III for preclin. studies and first-in-human clin. trials. A first approach relying on a chiral separation furnished the desired enantiomer of 1,3-diamine IV, precursor of sulfonamide I. An enantiomeric synthesis of IV using the Ellman’s chiral auxiliary coupled with an aza-Reformatsky reaction to control the stereochem. is also discussed. Coupling conditions of the final step involving EDCI to provide III under a cGMP process are detailed. An alternative approach using N-(1-methanesulfonyl)benzotriazole is also presented. The experimental process involved the reaction of 3-Nitro-4-chlorobenzenesulfonamide(cas: 97-09-6).Quality Control of 3-Nitro-4-chlorobenzenesulfonamide

The Article related to acylsulfonamide diamine telescoped process aza reformatsky coupling chemoselective amination, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 3-Nitro-4-chlorobenzenesulfonamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On December 30, 2009, Aissaoui, Hamed; Boss, Christoph; Koberstein, Ralf; Siegrist, Romain; Sifferlen, Thierry published a patent.Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide The title of the patent was 5,6,7,8-Tetrahydroimidazo[1,5-a]pyrazine compounds as orexin receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

The invention relates to 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives of formula I and to the use of such compounds as medicaments, especially as orexin (OX) receptor antagonists. Compounds of formula I wherein R4 is C1-4 alkyl; when R3 is cyclopropyl, then R2 is halo, CF3, C1-4 alkyl and vinyl, R1 is substituted phenyl; when R3 is C3-6 cycloalkyl-C1-4 alkyl, then R2 is halo, R1 is substituted phenyl; when R3 is -SO2-C1-4 alkyl, then R2 is halo, R1 is substituted phenyl; when R3 is -S-C1-4 alkyl, then R2 is halo, CF3 and vinyl, R1 is substituted phenyl; when R3 is C1-4 alkyl, then R2 is -SO0-2-C1-4 alkyl, R1 is substituted phenyl; when R3 is C1-4 alkoxy, then R2 is CF3, R1 is substituted phenyl; when R3 is CF3, then R2 is C1-4 alkyl, R1 is substituted phenyl; when R3 is C1-4 alkyl, then R2 is halo, R1 is substituted phenyl; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared via N-alkylation of 1-chloro-8-[2-(4-chloro-3-fluorophenyl)ethyl]-3-cyclopropyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine with toluene-4-sulfonic acid (S)-methylcarbamoylphenyl Me ester. All the invention compounds were evaluated for their OX receptor antagonistic activity. From the assay, it was determined that II exhibited the IC50 values of 43 nM and 11 nM against OX1 and OX2, resp. The experimental process involved the reaction of (S)-2-Hydroxy-N-methyl-2-phenylacetamide(cas: 65645-88-7).Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide

The Article related to tetrahydro imidazopyrazine compound preparation orexin receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On March 30, 2017, Ma, Dawei; Yu, Qiang; Yuan, Junying; Xia, Hongguang; Cai, Dongpo; Wang, Kailiang; Zhang, Chen; Xia, Shanghua published a patent.Application of 16230-24-3 The title of the patent was 2,4-Diamino-5-(trifluoromethyl)pyridine-1,3-diaminobenzene-acrylamide derivatives as EGFR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. And the patent contained the following:

The invention provides 2,4-diamino-5-(trifluoromethyl)pyridine-1,3-diaminobenzene-acrylamide derivatives of formula I as EGFR kinase inhibitors and the preparation method and use thereof. Compounds of formula I wherein X and Y are independently N, CH; provided that X and Y are not CH at the same time; R is (un)substituted 5- to 7-membered heterocyclic ring, -NH-(un)substituted 5- to 7-membered heterocyclic ring, etc.; and their preparation method, as well as their use as EGFR kinase inhibitors in the treatment of cancer thereof, are claimed. Compounds of formula I were prepared by using condensation and deacylation as the key steps. All the invention compounds were evaluated for their EGFR inhibitory activity. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Application of 16230-24-3

The Article related to trifluoromethyl pyridine diaminobenzene acrylamide preparation egfr inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On April 5, 2017, Ma, Dawei; Yu, Qiang; Yuan, Junying; Xia, Hongguang; Cai, Dongpo; Wang, Kailiang; Zhang, Chen; Xia, Shanghua published a patent.Application In Synthesis of N-(3-Aminophenyl)acrylamide The title of the patent was 2,4-Diamino-5-(trifluoromethyl)pyridine-1,3-diaminobenzene-acrylamide derivatives as EGFR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. And the patent contained the following:

The invention provides EGFR kinase inhibitor and its preparation method and application.Specifically, the invention provides a compound shown in formula (I), wherein the definition of each group is as noted in the instruction book.Described compound is the effective EGFR inhibitor. The invention provides 2,4-diamino-5-(trifluoromethyl)pyridine-1,3-diaminobenzene-acrylamide derivatives of formula I as EGFR kinase inhibitors and the preparation method and use thereof. Compounds of formula I wherein X and Y are independently N, CH; provided that X and Y are not CH at the same time; R is (un)substituted 5- to 7-membered heterocyclic ring, -NH-(un)substituted 5- to 7-membered heterocyclic ring, etc.; and their preparation method, as well as their use as EGFR kinase inhibitors in the treatment of cancer thereof, are claimed. Compounds of formula I were prepared by using condensation and deacylation as the key steps. All the invention compounds were evaluated for their EGFR inhibitory activity. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Application In Synthesis of N-(3-Aminophenyl)acrylamide

The Article related to trifluoromethyl pyridine diaminobenzene acrylamide preparation egfr inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application In Synthesis of N-(3-Aminophenyl)acrylamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

Ahmed, Ahmed A. M.; Mekky, Ahmed E. M.; Sanad, Sherif M. H. published an article in 2022, the title of the article was New piperazine-based bis(thieno[2,3-b]pyridine) and bis(pyrazolo[3,4-b]pyridine) hybrids linked to benzofuran units: Synthesis and in vitro screening of potential acetylcholinesterase inhibitors.Category: amides-buliding-blocks And the article contains the following content:

Two series of piperazine-based bis(thieno[2,3-b]pyridines) I (Y = CN, COMe, CONH2, COOEt, COPh) and bis(pyrazolo[3,4-b]pyridines) II (Z = H, Me, OMe, Cl, COOEt) were prepared in good yields, utilizing the appropriate bis(pyridinethione). The first series was obtained by reacting the previous synthon with different α-halogenated reagents, whereas the second series was produced by reacting the synthon with various hydrazonyl chlorides, and then cyclizing the resulting bis(hydrazonothioates). At 50 and 100μM concentrations, the two series were screened as potential acetylcholinesterase inhibitors. The reference donepezil had inhibition percentages of 90.7 and 93.5 at the tested concentrations Generally, bis(thieno[2,3-b]pyridine) series was found to be more effective than the other series of bis(pyrazolo[3,4-b]pyridine). Bis(thieno[2,3-b]pyridine-2-carbonitrile) inhibited acetylcholinesterase the best, with inhibition percentages of 55.2 and 88.4 at 50 and 100μM concentrations, resp. Furthermore, when tested at a concentration of 25μg/mL, the prior hybrid demonstrated the best DPPH antioxidant activity, with an inhibition percentage of 81.5 when compared to the reference ascorbic acid (inhibition percentage of 88.7). The experimental process involved the reaction of 2-Chloroacetamide(cas: 79-07-2).Category: amides-buliding-blocks

The Article related to piperazine thienopyridine pyrazolopyridine benzofuran preparation acetylcholinesterase inhibitor antioxidant, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: amides-buliding-blocks

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On April 30, 2015, Huang, Min-yi; Xu, Wei; Huang, Jun-jun; Huang, Ya-jian; Yuan, Mu published an article.Formula: C11H9NO3 The title of the article was Synthesis, crystal structure and biological activity of N-(2-hydroxy-3-(4-(2-methoxyphenyl)-piperazin-1-yl)propyl)quinoxaline-2-methanamide. And the article contained the following:

The title compound N-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)-quinoxaline-2-methanamide (I, C23H27N5O3, Mr = 421.50) was synthesized via a four-step reaction and characterized by 1H NMR, 13C NMR, ESIMS and single-crystal X-ray diffraction. The crystal is of monoclinic, space group P21/n with a = 12.108(2), b = 12.639(3), c = 14.601(3) Å, β = 104.87(3)°, V = 2,159.6(8) Å3, Z = 4, Dc = 1.296 g/cm3, S = 1.023, μ = 0.088 mm-1, F(000) = 896, R = 0.0392 and wR = 0.0983 for 2,836 observed reflections with I>2σ (I). The single-crystal X-ray structural anal. reveals that I is stabilized by intramol. and intermol. hydrogen bonds together with π-π interactions. The bioassay showed that I exhibited high selective activity for α1A/D vs. α1B-adrenoceptors subtype. The experimental process involved the reaction of 2-(Oxiran-2-ylmethyl)isoindoline-1,3-dione(cas: 5455-98-1).Formula: C11H9NO3

The Article related to methoxyphenylpiperazinylpropyl quinoxalinecarboxamide preparation adrenoceptor antagonistic activity crystal mol structure, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Formula: C11H9NO3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On June 27, 2022, Chen, Yantao; Kollback, Johanna; Aurell, Carl-Johan published an article.COA of Formula: C13H12N2O The title of the article was An Improved Synthesis of 1λ;6,2,4,6-Thiatriazine-1,3,5-trione Derivatives – the Sulfonimidamide-featured Triazinones. And the article contained the following:

N,N’-dicarbamoylation of 4-methylbenzenesulfonimidamide with carbonyldiimidazole, followed by a mono-nucleophilic substitution with amines and subsequential ring closure in one-pot, afforded 1λ6,2,4,6-thiatriazine-1,3,5-trione derivatives I [R = cyclohexyl, Ph, 3-pyridyl, etc.] in up to 83% yields. The protocol also worked well for aliphatic sulfonimidamides, such as Me sulfonimidamide. The experimental process involved the reaction of 1,3-Diphenylurea(cas: 102-07-8).COA of Formula: C13H12N2O

The Article related to thiatriazine dione derivative preparation, amine thiatriazine dione oxide tandem diacylation nucleophilic substitution cyclization, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Three Or More Hetero Atoms and other aspects.COA of Formula: C13H12N2O

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On April 9, 2015, Chen, Yi published a patent.Recommanded Product: 16230-24-3 The title of the patent was Preparation of substituted [(6-phenyl-4-methyl-3-oxo-3,4-dihydropyrazin-2-yl)amino]benzene derivatives as inhibitors of bruton’s tyrosine kinase. And the patent contained the following:

The present invention provides compounds I [R0 and R1 = independently H, alkyl, alkenyl, alkynyl, cycloalkyl, etc.; L = N(Rd)(CH2)m; Rd = H, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl; m = 0-4; R2 = H or alkyl; R3 = H, halo, alkyl, or hydroxyalkyl; R4 = W, X, Y or Z; R5, R6, R7, R8, R9, R10, R11 and R12 = independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, or alkoxy], or their N-oxides, pharmaceutically acceptable salts, solvates, polymorphs or tautomers. For example, compound II was prepared by coupling of compound III (preparation given) with compound IV (preparation given) followed by hydrolysis. The Kd value of compound II for bruton’s tyrosine kinase (BTK) was 0.86 nM, which clearly shows that compound II is a highly potent BTK inhibitor. The invention compounds are useful as inhibitors of bruton’s tyrosine kinase for the treatment of neoplastic disease, autoimmune disease and inflammatory disorder. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Recommanded Product: 16230-24-3

The Article related to phenylmethyloxodihydropyrazinylaminobenzene compound preparation bruton tyrosine kinase inhibitor, neoplastic disease autoimmune disease inflammatory disorder treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 16230-24-3

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On July 28, 2016, Chen, Yi published a patent.Safety of N-(3-Aminophenyl)acrylamide The title of the patent was Preparation of substituted [(6-phenyl-4-methyl-3-oxo-3,4-dihydropyrazin-2-yl)amino]benzene derivatives as selective Bruton’s tyrosine kinase inhibitors. And the patent contained the following:

The invention provides compounds I [R0 and R1 = independently H, alkyl, alkenyl, alkynyl, cycloalkyl, etc.; L = N(Rd)(CH2)m; Rd = H, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl; m = 0-4; R2 = H or alkyl; R3 = H, halo, alkyl, or hydroxyalkyl; R4 = W, X, Y or Z; R5, R6, R7, R8, R9, R10, R11 and R12 = independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, or alkoxy], or their N-oxides, pharmaceutically acceptable salts, solvates, polymorphs or tautomers. For example, compound II was prepared by coupling of compound III (preparation given) with compound IV (preparation given) followed by hydrolysis. The Kd value of compound II for Bruton’s tyrosine kinase (BTK) was 0.86 nM, which clearly shows that compound II is a highly potent BTK inhibitor. The invention compounds are useful as inhibitors of Bruton’s tyrosine kinase for the treatment of neoplastic disease, autoimmune disease and inflammatory disorder. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Safety of N-(3-Aminophenyl)acrylamide

The Article related to phenylmethyloxodihydropyrazinylaminobenzene compound preparation bruton tyrosine kinase inhibitor, neoplastic disease autoimmune disease inflammatory disorder treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of N-(3-Aminophenyl)acrylamide

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics

On February 28, 2021, Przybylek, Maciej; Walczak, Patrycja; Ziolkowska, Dorota; Grela, Izabela; Cysewski, Piotr published an article.Product Details of 144-80-9 The title of the article was Studies on the solid-liquid equilibria and intermolecular interactions Urea binary mixtures with Sulfanilamide and Sulfacetamide. And the article contained the following:

The binary phase diagrams of Sulfanilamide-Urea (SN-U) and Sulfacetamide-Urea (SC-U) were measured using differential scanning calorimetry technique (DSC). Both examined mixtures were found to form simple binary eutectics. The limited miscibility in the solid state observed by DSC, proving inability of co-crystallization in new multi-mol. form, was also confirmed using PXRD and FTIR-ATR measurements of solid dispersions obtained via liquid assisted co-grinding. The lack of intermol. complex formation in the crystals does not imply the lack of interactions in the liquid state. Detailed characteristics of potential homo- and hetero-mol. pairs were offered using ab initio and the first principle quantum chem. computations. The obtained results happened to be strongly dependent on the applied level of theory. The importance of including the zero point energy contributions and electron correlation corrections was emphasized. It was found that the mole fraction of hetero-complexes with urea is the highest among all other constituents of studied systems at their eutectic points. Finally, the importance of intermol. interaction leading to complexes formation in the liquid state at saturated position was documented by computed values of solvation Gibbs free energy. Based on computed trends it was inferred that the eutectic mixtures can be interpreted as such equilibrium for which mutual solvation of all components is maximized. The experimental process involved the reaction of N-((4-Aminophenyl)sulfonyl)acetamide(cas: 144-80-9).Product Details of 144-80-9

The Article related to sulfanilamide sulfacetamide urea solid liquid equilibrium intermol interaction, Thermodynamics, Thermochemistry, and Thermal Properties: Calorimetry, Thermal Analysis, Thermogravimetry and other aspects.Product Details of 144-80-9

Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics